Advertisement
Screener

Exelixis Inc (EXEL) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

Exelixis Inc Increase (Decrease) in Deferred Revenue

Exelixis Inc (EXEL) reported Increase (Decrease) in Deferred Revenue of $5.91 million for the 6-month period ending 2018-06-29, per its 10-Q filed 2018-08-01.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-01

  • Exelixis Inc increase (decrease) in deferred revenue for the quarter ending 2018-06-29 was $8.56M.
  • Exelixis Inc increase (decrease) in deferred revenue for the quarter ending 2018-03-30 was -$2.65M, a 107.55% decline year-over-year.
  • Exelixis Inc increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$7.45M, a 113.29% decline year-over-year.
  • Exelixis Inc increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$6.98M.
  • Exelixis Inc increase (decrease) in deferred revenue for fiscal 2017 was $13.74M, a 94.65% decline from fiscal 2016.
  • Exelixis Inc increase (decrease) in deferred revenue for fiscal 2016 was $256.76M.
  • Exelixis Inc increase (decrease) in deferred revenue for fiscal 2016 was $256.76M.
  • Exelixis Inc increase (decrease) in deferred revenue for fiscal 2016 was -$2.58M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2018-06-29$8.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
$5.91M
10-Q · filed 2018-08-01
2018-03-30-$2.65M
10-Q · filed 2018-05-02
2017-12-29$13.74M
10-K · filed 2018-02-26
2017-09-30-$7.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
-$14.43M
derived: sum of 2 quarters · filed 2017-11-01
$20.71M
10-Q · filed 2017-11-01
$25.96M
derived: sum of 4 quarters · filed 2018-05-02
2017-06-30-$6.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$28.16M
10-Q · filed 2017-08-02
$33.41M
derived: sum of 3 quarters · filed 2018-05-02
$89.45M
derived: sum of 4 quarters · filed 2018-05-02
2017-03-31$35.14M
10-Q · filed 2017-05-01
$40.39M
derived: sum of 2 quarters · filed 2018-05-02
$96.43M
derived: sum of 3 quarters · filed 2018-05-02
$93.10M
derived: sum of 4 quarters · filed 2018-05-02
2016-12-31$5.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$61.29M
derived: sum of 2 quarters · filed 2017-11-01
$57.96M
derived: sum of 3 quarters · filed 2017-11-01
$256.76M
10-K · filed 2017-02-27
2016-12-30$256.76M
10-K · filed 2018-02-26
2016-09-30$56.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$52.71M
derived: sum of 2 quarters · filed 2017-11-01
$251.51M
10-Q · filed 2017-11-01
$251.51M
derived: sum of 4 quarters · filed 2017-11-01
2016-06-30-$3.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$195.47M
10-Q · filed 2017-08-02
$195.47M
derived: sum of 3 quarters · filed 2017-08-02
$195.47M
derived: sum of 4 quarters · filed 2017-08-02
2016-03-31$198.80M
10-Q · filed 2017-05-01
$198.80M
derived: sum of 2 quarters · filed 2017-05-01
$198.80M
derived: sum of 3 quarters · filed 2017-05-01
$198.80M
derived: sum of 4 quarters · filed 2017-05-01
2016-01-01-$2.58M
10-K · filed 2018-02-26
2015-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$1.00K
derived: sum of 2 quarters · filed 2017-02-27
-$6.00K
derived: sum of 3 quarters · filed 2017-02-27
-$2.58M
10-K · filed 2017-02-27
2015-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
-$7.00K
derived: sum of 2 quarters · filed 2016-11-03
-$2.58M
10-Q · filed 2016-11-03
-$1.32M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30-$7.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$2.58M
10-Q · filed 2016-08-03
-$1.32M
derived: sum of 3 quarters · filed 2017-02-27
-$1.13M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31-$2.58M
10-Q · filed 2016-05-04
-$1.31M
derived: sum of 2 quarters · filed 2017-02-27
-$1.12M
derived: sum of 3 quarters · filed 2017-02-27
-$1.24M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$1.46M
derived: sum of 2 quarters · filed 2017-02-27
$1.34M
derived: sum of 3 quarters · filed 2017-02-27
$1.13M
10-K · filed 2017-02-27
2014-09-30$192.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10
$76.00K
derived: sum of 2 quarters · filed 2015-11-10
-$131.00K
10-Q · filed 2015-11-10
$302.00K
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30-$116.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11
-$323.00K
10-Q · filed 2015-08-11
$110.00K
derived: sum of 3 quarters · filed 2016-02-29
-$380.00K
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$207.00K
10-Q · filed 2015-04-30
$226.00K
derived: sum of 2 quarters · filed 2016-02-29
-$264.00K
derived: sum of 3 quarters · filed 2016-02-29
-$7.97M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$433.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$57.00K
derived: sum of 2 quarters · filed 2016-02-29
-$7.76M
derived: sum of 3 quarters · filed 2016-02-29
-$14.87M
10-K · filed 2016-02-29
2013-09-30-$490.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04
-$8.19M
derived: sum of 2 quarters · filed 2014-11-04
-$15.30M
10-Q · filed 2014-11-04
-$23.12M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30-$7.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31
-$14.81M
10-Q · filed 2014-07-31
-$22.63M
derived: sum of 3 quarters · filed 2015-03-02
-$30.44M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31-$7.11M
10-Q · filed 2014-05-01
-$14.92M
derived: sum of 2 quarters · filed 2015-03-02
-$22.74M
derived: sum of 3 quarters · filed 2015-03-02
-$30.55M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31-$7.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$15.63M
derived: sum of 2 quarters · filed 2015-03-02
-$23.44M
derived: sum of 3 quarters · filed 2015-03-02
-$41.92M
10-K · filed 2015-03-02
2012-09-30-$7.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30
-$15.63M
derived: sum of 2 quarters · filed 2013-10-30
-$34.11M
10-Q · filed 2013-10-30
-$103.47M
derived: sum of 4 quarters · filed 2014-02-20
2012-06-30-$7.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
-$26.29M
10-Q · filed 2013-08-06
-$95.66M
derived: sum of 3 quarters · filed 2014-02-20
-$220.32M
derived: sum of 4 quarters · filed 2014-02-20
2012-03-31-$18.48M
10-Q · filed 2013-05-07
-$87.85M
derived: sum of 2 quarters · filed 2014-02-20
-$212.51M
derived: sum of 3 quarters · filed 2014-02-20
-$237.61M
derived: sum of 4 quarters · filed 2014-02-20
2011-12-31-$69.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20
-$194.03M
derived: sum of 2 quarters · filed 2014-02-20
-$219.13M
derived: sum of 3 quarters · filed 2014-02-20
-$244.53M
10-K · filed 2014-02-20
2011-09-30-$124.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
-$149.76M
derived: sum of 2 quarters · filed 2012-11-07
-$175.16M
10-Q · filed 2012-11-07
-$139.91M
derived: sum of 4 quarters · filed 2013-02-21
2011-06-30-$25.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02
-$50.50M
10-Q · filed 2012-08-02
-$15.24M
derived: sum of 3 quarters · filed 2013-02-21
-$58.15M
derived: sum of 4 quarters · filed 2013-02-21
2011-03-31-$25.40M
10-Q · filed 2012-05-03
$9.86M
derived: sum of 2 quarters · filed 2013-02-21
-$33.05M
derived: sum of 3 quarters · filed 2013-02-21
2010-12-31$35.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
-$7.66M
derived: sum of 2 quarters · filed 2013-02-21
-$42.95M
10-K · filed 2013-02-21
2010-09-30-$42.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27
-$78.20M
10-Q · filed 2011-10-27
2010-06-30-$35.29M
10-Q · filed 2011-08-04
2009-12-31$85.78M
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78